ACC In Brief
This article was originally published in The Tan Sheet
PREVU(x) POC in action: A skin sterol testing method was successfully employed to detect subclinical vascular disease, according to an 81-subject study presented by Wendy Tzou, MD, University of Wisconsin Medical School, et al., at the American College of Cardiology Annual Scientific Session in Orlando, Fla. March 7. Carotid intima media thickness, "a well-established marker of atherosclerosis," was significantly higher among patients in the population exhibiting the highest skin sterol measurement using PREVU(x) Point of Care test, according to the test's marketer, Toronto-based IMI. The data "confirm that skin sterol testing has the ability to help identify patients at risk of heart disease non-invasively and cost effectively," CEO Brent Norton asserts. IMI signed a marketing agreement with McNeil last year and is developing an OTC version of the product (1"The Tan Sheet" June 7, 2004, p. 10)...
You may also be interested in...
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: